Photodynamic therapy with half dose verteporfin for central serous chorioretinopathy:Prospective intervention trial
Phase 2
- Conditions
- Central serous chorioretinopathy
- Registration Number
- JPRN-UMIN000002229
- Lead Sponsor
- agoya University School of Medicine Department of Ophthalmology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria, or hypersensitivity to artificial illumination 4. macular diseases other than CSC 5. others (inappropriate case judged by investigator or subinvestigators)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method resolution of serous retinal detachment of 4 days, 1 month, 3 months and 1 year after PDT
- Secondary Outcome Measures
Name Time Method 1)visual acuity 2)optical coherence tomography 3)amplitudes and implicit time of a-wave, b-wave and odcillatory potentials recorded by focal macula electroretinogram 4)visual field 5)fluorescein angiography 6)indocyanine green angiography time of assessment 1)-5) : 4 days, 1 month, 3 months and 1 year after PDT 6),7) : 1 month, 3 months and 1 year after PDT